Perspective Therapeutics Introduces "Pre-Targeting" Theranostic Technology Platform
Perspective Therapeutics(CATX) Newsfilter·2024-02-01 13:00Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based Radiopharmaceutical Approach SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) -- -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has executed an exclusi ...